Morphic says Johnson & Johnson unit ended research collaboration

Jan. 23, 2023 7:15 AM ETMorphic Holding, Inc. (MORF), JNJABBVBy: Dulan Lokuwithana, SA News Editor

Janssen headquarters in Silicon Valley

Sundry Photography

  • Morphic Holding (NASDAQ:MORF), a biotech focused on integrin therapeutics, announced that Johnson & Johnson’s (NYSE:JNJ) Janssen unit has opted to terminate the research and option agreement with its subsidiary Morphic Therapeutic.
  • Under the 2019 collaboration, Morphic granted Janssen

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.